AMPK pathway / NLRP3 inflammasome (dual)

Class

AMPK activator + NLRP3 inflammasome inhibitor (berberine-ursodeoxycholate ionic salt)

This mechanism combines two distinct but complementary activities within a single molecule: activation of AMP-activated protein kinase (AMPK) and inhibition of the NLRP3 inflammasome. AMPK is a cellular energy sensor that becomes active when energy reserves are low; once activated, it shifts cells away from energy-storing processes (such as fat and glucose synthesis) and toward energy-generating ones (such as fatty acid breakdown), while also improving how cells take up and use glucose. The NLRP3 inflammasome is a protein complex that assembles inside cells in response to metabolic and other danger signals, triggering release of inflammatory messengers that drive tissue damage. In chronic metabolic diseases such as fatty liver disease, insulin resistance and inflammation typically progress together, each reinforcing the other. A molecule that both improves metabolic handling of fat and glucose (via AMPK) and dampens the inflammatory amplification loop (via NLRP3 inhibition) is designed to address both drivers rather than one in isolation. This dual profile reflects the biological rationale that metabolic dysfunction and chronic low-grade inflammation are intertwined processes, particularly in conditions like non-alcoholic fatty liver disease, where fat accumulation, insulin resistance, and inflammasome-driven liver injury coexist and often require more than a single-pathway intervention to meaningfully alter disease course.